{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T10:55:39Z","timestamp":1791111339217,"version":"4.1.0"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T00:00:00Z","timestamp":1720224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100008271","name":"LEO Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008271","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Drug persistence is a crucial aspect of treatment success in psoriasis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To record real-world evidence concerning drug survival of biologic agents used for psoriasis treatment and to detect associated modifying factors in Greece.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was a retrospective cohort study based on data extracted from the nationwide Greek prescription system. Included patients had psoriasis, with or without concomitant psoriatic arthritis (PsA), and had initiated biologics between 1 January 2016 and 31 December 2020.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We included 8819 patients who received 13 359 treatment lines. Among them, 76.8% of patients were biologic naive and 16.5% were diagnosed with concomitant PsA. The overall median drug survival was 34.3 months [95% confidence interval (CI) 32.6\u201336.5]. Drug persistence at 12, 24, 36 and 48 months of follow-up was 71.9%, 57.7%, 49.0% and 43.7%, respectively. Patients receiving brodalumab had the highest drug survival rate in the first 2 years, while secukinumab had the highest rates beyond this period. Overall, drug survival rates were higher in the first treatment line (median 51.1 months, 95% CI 47.1 to not reached) than in the second line and onwards (median 21.7 months, 95% CI 20.0\u201323.5). Treatment line, PsA status, age and sex were found to significantly affect drug survival rates.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our findings confirm previous reports regarding the importance of efficient first-line biologics and the vulnerability of patients to coexistent PsA. The use of antibodies against interleukins confers high drug survival rates. These results will assist clinical management of patients with psoriasis in Greece.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ced\/llae240","type":"journal-article","created":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T13:36:58Z","timestamp":1720273018000},"page":"1573-1581","source":"Crossref","is-referenced-by-count":2,"title":["Drug survival of biologics in patients with psoriasis: real-world evidence for Greece during the period 2016\u20132020"],"prefix":"10.1093","volume":"49","author":[{"given":"Elizabeth","family":"Lazaridou","sequence":"first","affiliation":[{"name":"Second Department of Dermatology, Aristotle University School of Medicine , Thessaloniki ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Kourlaba","sequence":"additional","affiliation":[{"name":"Department of Nursing, University of Peloponnese , Tripoli ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8347-218X","authenticated-orcid":false,"given":"Stylianos","family":"Ravanidis","sequence":"additional","affiliation":[{"name":"ECONCARE , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Gounelas","sequence":"additional","affiliation":[{"name":"ECONCARE , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garyfallia","family":"Stefanou","sequence":"additional","affiliation":[{"name":"ECONCARE , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasios","family":"Tsolakidis","sequence":"additional","affiliation":[{"name":"IDIKA SA \u2013 e-Government Center for Social Security Services , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Mathioudakis","sequence":"additional","affiliation":[{"name":"IDIKA SA \u2013 e-Government Center for Social Security Services , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Apalla","sequence":"additional","affiliation":[{"name":"Second Department of Dermatology, Aristotle University School of Medicine , Thessaloniki ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,6]]},"reference":[{"key":"2024112216162859800_llae240-B1","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.jaad.2015.02.1099","article-title":"Evaluating the economic burden of psoriasis in the United States","volume":"72","author":"Vanderpuye-Orgle","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"2024112216162859800_llae240-B2","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s12955-018-1007-7","article-title":"The association of socioeconomic and clinical characteristics with health-related quality of life in patients with psoriasis: a cross-sectional study","volume":"16","author":"Jung","year":"2018","journal-title":"Health Qual Life Outcomes"},{"key":"2024112216162859800_llae240-B3","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Menter","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2024112216162859800_llae240-B4","doi-asserted-by":"crossref","first-page":"743180","DOI":"10.3389\/fmed.2021.743180","article-title":"The global, regional, and national burden of psoriasis: results and insights from the Global Burden of Disease 2019 Study","volume":"8","author":"Damiani","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2024112216162859800_llae240-B5","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1093\/rheumatology\/ket363","article-title":"Age at disease onset: a key factor for understanding psoriatic disease","volume":"53","author":"Queiro","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"2024112216162859800_llae240-B6","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s13555-019-0290-5","article-title":"The potential benefits of certolizumab pegol in patients with concurrent psoriatic arthritis and chronic plaque psoriasis: a case series and review of the literature","volume":"9","author":"Rutkowski","year":"2019","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2024112216162859800_llae240-B7","doi-asserted-by":"crossref","first-page":"195","DOI":"10.4103\/ijd.IJD_233_16","article-title":"Secukinumab \u2013 first in class interleukin-17A inhibitor for the treatment of psoriasis","volume":"62","author":"Godse","year":"2017","journal-title":"Indian J Dermatol"},{"key":"2024112216162859800_llae240-B8","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.2147\/DDDT.S113683","article-title":"Spotlight on brodalumab in the treatment of moderate-to-severe plaque psoriasis: design, development, and potential place in therapy","volume":"11","author":"Roman","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"2024112216162859800_llae240-B9","doi-asserted-by":"crossref","first-page":"535","DOI":"10.4161\/mabs.3.6.17815","article-title":"Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders","volume":"3","author":"Benson","year":"2011","journal-title":"MAbs"},{"key":"2024112216162859800_llae240-B10","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1001\/jamadermatol.2019.4029","article-title":"Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis","volume":"156","author":"Armstrong","year":"2020","journal-title":"JAMA Dermatol"},{"key":"2024112216162859800_llae240-B11","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10245732","article-title":"Comparison of treatment goals between users of biological and non-biological therapies for treatment of psoriasis in Japan","volume":"10","author":"Okubo","year":"2021","journal-title":"J Clin Med"},{"key":"2024112216162859800_llae240-B12","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1007\/s13555-021-00616-7","article-title":"Drug persistence of biologic treatments in psoriasis: a Swedish national population study","volume":"11","author":"Schmitt-Egenolf","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2024112216162859800_llae240-B13","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/bjd.18981","article-title":"Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)","volume":"183","author":"Yiu","year":"2020","journal-title":"Br J Dermatol"},{"key":"2024112216162859800_llae240-B14","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/bjd.19701","article-title":"Biologic drug survival rates in the era of anti-interleukin-17 antibodies: a time-period-adjusted registry analysis","volume":"184","author":"Graier","year":"2021","journal-title":"Br J Dermatol"},{"key":"2024112216162859800_llae240-B15","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1111\/jdv.15600","article-title":"Expert consensus on the persistence of biological treatments in moderate-to-severe psoriasis","volume":"33","author":"de la Cueva Dobao","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024112216162859800_llae240-B16","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/bjd.19189","article-title":"Biologics for psoriasis: what does drug survival tell us?","volume":"183","author":"Veysey","year":"2020","journal-title":"Br J Dermatol"},{"key":"2024112216162859800_llae240-B17","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18112297","article-title":"Old and new biological therapies for psoriasis","volume":"18","author":"Ronholt","year":"2017","journal-title":"Int J Mol Sci"},{"key":"2024112216162859800_llae240-B18","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1111\/j.1365-2133.2011.10213.x","article-title":"Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris","volume":"164","author":"Gniadecki","year":"2011","journal-title":"Br J Dermatol"},{"key":"2024112216162859800_llae240-B19","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1111\/jdv.13611","article-title":"Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)","volume":"30","author":"Menter","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024112216162859800_llae240-B20","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1080\/09546634.2022.2082354","article-title":"Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors \u2013 brodalumab, ixekizumab, and secukinumab: real-world data from the Czech Republic BIOREP registry","volume":"33","author":"Kojanova","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"2024112216162859800_llae240-B21","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40257-021-00598-4","article-title":"Drug survival of IL-12\/23, IL-17 and IL-23 inhibitors for psoriasis treatment: a retrospective multi-country, multicentric cohort study","volume":"22","author":"Torres","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"2024112216162859800_llae240-B22","doi-asserted-by":"crossref","first-page":"2229465","DOI":"10.1080\/09546634.2023.2229465","article-title":"Treatment persistence of interleukin-17 inhibitor class drugs among patients with psoriasis in Japan: a retrospective database study","volume":"34","author":"Wang","year":"2023","journal-title":"J Dermatolog Treat"},{"key":"2024112216162859800_llae240-B23","doi-asserted-by":"crossref","first-page":"1196966","DOI":"10.3389\/fmed.2023.1196966","article-title":"Brodalumab for the treatment of plaque psoriasis in a real-life setting: a 3 years multicenter retrospective study-IL PSO (Italian landscape psoriasis)","volume":"10","author":"Gargiulo","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"2024112216162859800_llae240-B24","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s40268-023-00422-w","article-title":"Single-centre real-world study on drug survival and effectiveness of brodalumab for treatment of psoriasis and psoriatic arthritis","volume":"23","author":"Elgaard","year":"2023","journal-title":"Drugs R D"},{"key":"2024112216162859800_llae240-B25","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/jvc2.173","article-title":"Real-world drug survival of brodalumab, in patients with psoriasis switched from ixekizumab: results of a single centre retrospective study (BroSwitch)","volume":"2","author":"Bethlem","year":"2023","journal-title":"JEADV Clin Pract"},{"key":"2024112216162859800_llae240-B26","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1111\/jdv.16202","article-title":"Real-world data from a single Greek centre on the use of secukinumab in plaque psoriasis: effectiveness, safety, drug survival, and identification of patients that sustain optimal response","volume":"34","author":"Rompoti","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024112216162859800_llae240-B27","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/jdv.18825","article-title":"Brodalumab in plaque psoriasis: real-world data on effectiveness, safety and clinical predictive factors of initial response and drug survival over a period of 104 weeks","volume":"37","author":"Rompoti","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024112216162859800_llae240-B28","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1590\/abd1806-4841.20175603","article-title":"Moderate to severe psoriasis treatment challenges through the era of biological drugs","volume":"92","author":"Vide","year":"2017","journal-title":"An Bras Dermatol"},{"key":"2024112216162859800_llae240-B29","doi-asserted-by":"crossref","first-page":"e001399","DOI":"10.1136\/rmdopen-2020-001399","article-title":"Comparative effectiveness of biologics and targeted therapies for psoriatic arthritis","volume":"7","author":"Zhang","year":"2021","journal-title":"RMD Open"},{"key":"2024112216162859800_llae240-B30","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1001\/jamadermatol.2022.2909","article-title":"Drug survival associated with effectiveness and safety of treatment with guselkumab, ixekizumab, secukinumab, ustekinumab, and adalimumab in patients with psoriasis","volume":"158","author":"Yiu","year":"2022","journal-title":"JAMA Dermatol"},{"key":"2024112216162859800_llae240-B31","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1038\/jid.2015.208","article-title":"Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)","volume":"135","author":"Warren","year":"2015","journal-title":"J Invest Dermatol"},{"key":"2024112216162859800_llae240-B32","doi-asserted-by":"crossref","first-page":"584","DOI":"10.3390\/medicina56110584","article-title":"Ustekinumab drug survival in patients with psoriasis: a retrospective study of real clinical practice","volume":"56","author":"Galache Osuna","year":"2020","journal-title":"Medicina (Kaunas)"},{"key":"2024112216162859800_llae240-B33","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.3390\/ijms21051690","article-title":"Efficacy and safety of biologics for psoriasis and psoriatic arthritis and their impact on comorbidities: a literature review","volume":"21","author":"Kamata","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2024112216162859800_llae240-B34","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.jaad.2016.01.037","article-title":"ORBIT (Outcome and Retention Rate of Biologic Treatments for Psoriasis): a retrospective observational study on biologic drug survival in daily practice","volume":"74","author":"Vilarrasa","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"2024112216162859800_llae240-B35","doi-asserted-by":"crossref","first-page":"e731","DOI":"10.1093\/oncolo\/oyac114","article-title":"Rationale, strengths, and limitations of real-world evidence in oncology: a Canadian review and perspective","volume":"27","author":"Azoulay","year":"2022","journal-title":"Oncologist"},{"key":"2024112216162859800_llae240-B36","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1111\/bjd.13087","article-title":"\u2018Happy\u2019 drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the BioCAPTURE network","volume":"171","author":"van den Reek","year":"2014","journal-title":"Br J Dermatol"},{"key":"2024112216162859800_llae240-B37","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jaad.2019.03.048","article-title":"Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis","volume":"81","author":"Egeberg","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2024112216162859800_llae240-B38","first-page":"479","article-title":"Health care utilization and cost associated with biologic treatment patterns among patients with moderate to severe psoriasis: analyses from a large U.S. claims database","volume":"25","author":"Feldman","year":"2019","journal-title":"J Manag Care Spec Pharm"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llae240\/58941509\/llae240.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/49\/12\/1573\/60790512\/llae240.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/49\/12\/1573\/60790512\/llae240.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T16:17:18Z","timestamp":1732292238000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/49\/12\/1573\/7708697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,6]]},"references-count":38,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,7,6]]},"published-print":{"date-parts":[[2024,11,22]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llae240","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12]]},"published":{"date-parts":[[2024,7,6]]}}}